Company research
Glucotrack, Inc.
CIK 1506983Updated Sep 24, 2026
SecurityGCTK · NASDAQ · equity
Historical securities (1)
IGAP · OTC · equity · closed Mar 11, 2022Name history
Integrity Applications, Inc. · through Dec 9, 2021
GCTK price & chart
Loading TradingView…
NASDAQ:GCTK on TradingView ↗About the company
The Company was incorporated on May 18, 2010 under the laws of the State of Delaware. We are a medical device company focused on the development of an implantable continuous blood glucose monitor (“CBGM”) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the “Glucotrack CBGM”).
In the news
E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing ↗
Recent filings
425 filing
Regulation FD Disclosure
Items 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
S-1 filing
Entry into a Material Definitive Agreement · Submission of Matters to a Vote of Security Holders
Items 1.01, 5.07, 9.01
Show 5 more recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.03, 3.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02
SCHEDULE 13G filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 5.03, 8.01, 9.01
425 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 7,838,000Source | 5,932,000Source | 4,905,000Source | 2,438,000Source |
| Property, Plant and Equipment, NetUSD | 138,000Source | 95,000Source | 27,000Source | 40,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,383,000Source | 5,617,000Source | 4,492,000Source | 2,312,000Source |
| Assets, CurrentUSD | 7,667,000Source | 5,768,000Source | 4,868,000Source | 2,379,000Source |
| Operating Lease, Right-of-Use AssetUSD | 33,000Source | 59,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,010,000Source | 18,932,000Source | 1,708,000Source | 1,208,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 20,000Source | 15,000Source |
| Retained Earnings (Accumulated Deficit)USD | -151,838,000Source | -132,450,000Source | -109,853,000Source | -101,901,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 41,000Source | -8,000Source | 16,000Source | 17,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,828,000Source | -13,000,000Source | 3,197,000Source | 1,230,000Source |
| Additional Paid in Capital, Common StockUSD | 151,080,000Source | 119,229,000Source | 112,966,000Source | 103,095,000Source |
| Liabilities and EquityUSD | 7,838,000Source | 5,932,000Source | 4,905,000Source | 2,438,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,773,000Source | 1,275,000Source | 1,512,000Source | 1,013,000Source |
| Operating Lease, Liability, CurrentUSD | 28,000Source | 26,000Source | — | — |
| Accounts Payable, CurrentUSD | 1,317,000Source | 992,000Source | 839,000Source | 672,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,000Source | 33,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 231,000Source | 203,000Source | 196,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | — | 325,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 211,000Source | 173,000Source | 281,000Source | 439,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 325,000Source | 263,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -15,240,000Source | -12,490,000Source | -6,558,000Source | -3,729,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -96,000Source | -104,000Source | — | 1,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 96,000Source | 104,000Source | — | 1,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 17,043,000Source | 13,743,000Source | 8,730,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,756,000Source | 1,125,000Source | 2,171,000Source | -3,782,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 5,627,000Source | 4,502,000Source | 2,331,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 52,000Source | 62,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 204,000Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | 628,000Source | — | — |
| DepreciationUSD | 42,000Source | 36,000Source | 13,000Source | 23,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | -3,267,000Source | -798,000Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | -16,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | -1,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | -4,758,000Source | — | — |
| General and Administrative ExpenseUSD | 6,277,000Source | 4,655,000Source | 2,278,000Source | 2,465,000Source |
| Net Income (Loss) Attributable to ParentUSD | -19,388,000Source | -22,597,000Source | -7,097,000Source | -4,435,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -22,597,000Source | 7,952,000Source | — |
| Nonoperating Income (Expense)USD | -3,298,000Source | — | — | — |
| Operating ExpensesUSD | 16,090,000Source | 14,547,000Source | 7,104,000Source | 4,432,000Source |
| Other Nonoperating Income (Expense)USD | 26,000Source | 14,000Source | — | -14,000Source |
| Payments for Repurchase of WarrantsUSD | 166,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -16,090,000Source | -14,547,000Source | -7,104,000Source | -4,432,000Source |
| Other Nonoperating Income (Expense)USD | 26,000Source | 14,000Source | — | -14,000Source |
| Net Income (Loss) Attributable to ParentUSD | -19,388,000Source | -22,597,000Source | -7,097,000Source | -4,435,000Source |
| Earnings Per Share, BasicUSD per share | 31.22Source | 68.44Source | 0.38Source | 0.29Source |
| Earnings Per Share, DilutedUSD per share | 31.22Source | 68.44Source | 0.38Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 621,094Source | 330,171Source | 20,760,266Source | 15,474,660Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 621,094Source | 330,171Source | 20,760,266Source | — |
| Additional Financial Items | ||||
| Gain (Loss) Related to Litigation SettlementUSD | — | -4,758,000Source | — | — |
| General and Administrative ExpenseUSD | 6,277,000Source | 4,655,000Source | 2,278,000Source | 2,465,000Source |
| Interest ExpenseUSD | — | 44,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -22,597,000Source | 7,952,000Source | — |
| Nonoperating Income (Expense)USD | -3,298,000Source | — | — | — |
| Operating ExpensesUSD | 16,090,000Source | 14,547,000Source | 7,104,000Source | 4,432,000Source |
| Other ExpensesUSD | — | 17,000Source | — | — |
| Research and Development ExpenseUSD | 9,813,000Source | 9,499,000Source | 4,704,000Source | 1,967,000Source |
| Selling and Marketing ExpenseUSD | — | — | 122,000Source | — |
Offerings
Registration 333-299000
Registration 333-290587
Filing attachments
ex99-1.htm · 8-K · 2026-09-23
Exhibit 99.1 Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities RUTHERFORD, N.J., and LA JOLLA, CA: Sept. 23, 2026 - Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets. A Clear View of Who We Are A Message From Our CEO, Eri…
Read attachment ↗ex107.htm · S-1 · 2026-09-18
Calculation of Filing Fee Tables S-1 Glucotrack, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee R…
Read attachment ↗ex4-1.htm · 8-K · 2026-09-14
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO WARRANT TO PURCHASE COMMON STOCK This AMENDMENT NO. 1 TO WARRANT TO PURCHASE COMMON STOCK, dated as of September 14, 2026 (this “ Amendment ”), amends that certain WARRANT TO PURCHASE COMMON STOCK (the “ Warrant ”), dated as of August 4, 2026, issued by Glucotrack, Inc., a Delaware corporation (the “ Company ”), for the benefit of, the registered holder thereof or its permitted assigns (“ Holder ”). The Company and Holder are referre…
Read attachment ↗ex4-1.htm · 8-K · 2026-09-11
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTI…
Read attachment ↗ex4-2.htm · 8-K · 2026-09-11
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABL…
Read attachment ↗ex4-3.htm · 8-K · 2026-09-11
EX-4.3 4 ex4-3.htm EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABL…
Read attachment ↗